Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KBV Research | PRODUCT CODE: 1101878

Cover Image

PUBLISHER: KBV Research | PRODUCT CODE: 1101878

LAMEA Intravenous Immunoglobulin Market Size, Share & Industry Trends Analysis Report By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, and Others), By Application, By Country and Growth Forecast, 2022 - 2028

PUBLISHED:
PAGES: 81 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1500
PDF (Site License)
USD 1800
PDF (Enterprisewide License)
USD 2520

Add to Cart

The Latin America, Middle East and Africa Intravenous Immunoglobulin Market would witness market growth of 9.9% CAGR during the forecast period (2022-2028).

Immunoglobulin is found in the plasma of the blood. It contains antibodies that help it fight pathogens and disease. This component can be separated when people give blood. Then it'll be injected into a vein in the arm, known as an IV. If a person obtains IVIg, the immune system will be strengthened, allowing the person to fight infections and stay healthy. Liquid immunoglobulin is extracted from the blood plasma of healthy donors who have been screened. Serious illnesses like hepatitis and AIDS are evaluated in the plasma. Before being used for IVIg therapy, the plasma is cleansed.

Prepared immunoglobulin is infused into the veins throughout the therapy. A needle is used to enter the vein by a health care provider. The drug will then be injected into the arm through a tube from a bag. This can take anything from 2 to 4 hours. To receive therapy, the patient is most likely to go to an infusion center, hospital, clinic, or doctor's office. A medical practitioner may be able to treat a patient at home on occasion. Treatments are usually given every 3 to 4 weeks to keep the immune system robust.

The region's population is suffering from various types of diseases as well as witnessing an increase in mortality rate. This factor boosts the requirement of advanced medical technology like intravenous immunoglobulin in the medical sector of the region. The United Arab Emirates (UAE) is a rapidly evolving country with a diverse population with various educational backgrounds, religious beliefs, and cultural traditions, leading to more making of population-based public health policies. In the United Arab Emirates, a variety of public health issues play a significant role in morbidity and death.

The region has experienced considerable economic and industrial development, leading to an increase in the affluence of the Emirati population and a switch from a traditional lifestyle to a modern and technology-driven lifestyle marked by lowered occupational, household, and leisure-time physical activity, as well as excessive consumption of energy-dense convenience foods with low nutritional value.

The Brazil market dominated the LAMEA Intravenous Immunoglobulin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $305.4 million by 2028. The Argentina market is anticipated to grow at a CAGR of 10.5% during (2022 - 2028). Additionally, The UAE market would showcase a CAGR of 9.6% during (2022 - 2028).

Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty Pharmacy, and Others. Based on Application, the market is segmented into Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia & Myasthenia Gravis, Congenital AIDS & Multifocal Motor Neuropathy, Kawasaki Disease, Guillain-Barre Syndrome, Immune thrombocytopenia (ITP), and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Grifols, S.A., Takeda Pharmaceutical Company Limited, Baxter International, Inc., Biotest AG (Tiancheng International Investment Limited), LFB S.A., CSL Limited (CSL Behring), Octapharma AG, Kedrion S.p.A, and Bayer AG.

Scope of the Study

Market Segments covered in the Report:

By Distribution Channel

  • Hospital Pharmacy
  • Specialty Pharmacy
  • Others

By Application

  • Immunodeficiency Diseases
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Hypogammaglobulinemia
  • Chronic Lymphocytic Leukemia & Myasthenia Gravis
  • Congenital AIDS & Multifocal Motor Neuropathy
  • Kawasaki Disease
  • Guillain-Barre Syndrome
  • Immune thrombocytopenia (ITP)
  • Others

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Baxter International, Inc.
  • Biotest AG (Tiancheng International Investment Limited)
  • LFB S.A.
  • CSL Limited (CSL Behring)
  • Octapharma AG
  • Kedrion S.p.A
  • Bayer AG

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 LAMEA Intravenous Immunoglobulin Market, by Distribution Channel
    • 1.4.2 LAMEA Intravenous Immunoglobulin Market, by Application
    • 1.4.3 LAMEA Intravenous Immunoglobulin Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. LAMEA Intravenous Immunoglobulin Market by Distribution Channel

  • 3.1 LAMEA Hospital Pharmacy Market by Country
  • 3.2 LAMEA Specialty Pharmacy Market by Country
  • 3.3 LAMEA Others Market by Country

Chapter 4. LAMEA Intravenous Immunoglobulin Market by Application

  • 4.1 LAMEA Immunodeficiency Diseases Market by Country
  • 4.2 LAMEA Chronic Inflammatory Demyelinating Polyneuropathy Market by Country
  • 4.3 LAMEA Hypogammaglobulinemia Market by Country
  • 4.4 LAMEA Chronic Lymphocytic Leukemia & Myasthenia Gravis Market by Country
  • 4.5 LAMEA Congenital AIDS & Multifocal Motor Neuropathy Market by Country
  • 4.6 LAMEA Kawasaki Disease Market by Country
  • 4.7 LAMEA Guillain-Barre Syndrome Market by Country
  • 4.8 LAMEA Immune thrombocytopenia (ITP) Market by Country
  • 4.9 LAMEA Others Market by Country

Chapter 5. LAMEA Intravenous Immunoglobulin Market by Country

  • 5.1 Brazil Intravenous Immunoglobulin Market
    • 5.1.1 Brazil Intravenous Immunoglobulin Market by Distribution Channel
    • 5.1.2 Brazil Intravenous Immunoglobulin Market by Application
  • 5.2 Argentina Intravenous Immunoglobulin Market
    • 5.2.1 Argentina Intravenous Immunoglobulin Market by Distribution Channel
    • 5.2.2 Argentina Intravenous Immunoglobulin Market by Application
  • 5.3 UAE Intravenous Immunoglobulin Market
    • 5.3.1 UAE Intravenous Immunoglobulin Market by Distribution Channel
    • 5.3.2 UAE Intravenous Immunoglobulin Market by Application
  • 5.4 Saudi Arabia Intravenous Immunoglobulin Market
    • 5.4.1 Saudi Arabia Intravenous Immunoglobulin Market by Distribution Channel
    • 5.4.2 Saudi Arabia Intravenous Immunoglobulin Market by Application
  • 5.5 South Africa Intravenous Immunoglobulin Market
    • 5.5.1 South Africa Intravenous Immunoglobulin Market by Distribution Channel
    • 5.5.2 South Africa Intravenous Immunoglobulin Market by Application
  • 5.6 Nigeria Intravenous Immunoglobulin Market
    • 5.6.1 Nigeria Intravenous Immunoglobulin Market by Distribution Channel
    • 5.6.2 Nigeria Intravenous Immunoglobulin Market by Application
  • 5.7 Rest of LAMEA Intravenous Immunoglobulin Market
    • 5.7.1 Rest of LAMEA Intravenous Immunoglobulin Market by Distribution Channel
    • 5.7.2 Rest of LAMEA Intravenous Immunoglobulin Market by Application

Chapter 6. Company Profiles

  • 6.1 Grifols, S.A
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Regional & Segmental Analysis
    • 6.1.4 Research & Development Expenses
    • 6.1.5 Recent strategies and developments:
      • 6.1.5.1 Product Launches and Product Expansions:
      • 6.1.5.2 Acquisition and Mergers:
  • 6.2 Takeda Pharmaceutical Company Limited
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Regional Analysis
    • 6.2.4 Research & Development Expense
    • 6.2.5 Recent strategies and developments:
      • 6.2.5.1 Approvals and Trials:
  • 6.3 Baxter International, Inc.
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Regional Analysis
    • 6.3.4 Research & Development Expense
  • 6.4 Biotest AG (Tiancheng International Investment Limited)
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Segmental and Regional Analysis
    • 6.4.4 Research & Development Expense
  • 6.5 LFB S.A.
    • 6.5.1 Company Overview
    • 6.5.2 Recent strategies and developments:
      • 6.5.2.1 Partnerships, Collaborations, and Agreements:
  • 6.6 CSL Limited (CSL Behring)
    • 6.6.1 Company Overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Segmental and Regional Analysis
    • 6.6.4 Research & Development Expense
  • 6.7 Octapharma AG
    • 6.7.1 Company Overview
    • 6.7.2 Recent strategies and developments:
      • 6.7.2.1 Approvals and Trials:
  • 6.8 Kedrion S.p.A
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Segmental and Regional Analysis
    • 6.8.4 Research & Development Expenses
  • 6.9 Bayer AG
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Segmental and Regional Analysis
    • 6.9.4 Research & Development Expense

LIST OF TABLES

  • TABLE 1 LAMEA Intravenous Immunoglobulin Market, 2018 - 2021, USD Million
  • TABLE 2 LAMEA Intravenous Immunoglobulin Market, 2022 - 2028, USD Million
  • TABLE 3 LAMEA Intravenous Immunoglobulin Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 4 LAMEA Intravenous Immunoglobulin Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 5 LAMEA Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
  • TABLE 6 LAMEA Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
  • TABLE 7 LAMEA Specialty Pharmacy Market by Country, 2018 - 2021, USD Million
  • TABLE 8 LAMEA Specialty Pharmacy Market by Country, 2022 - 2028, USD Million
  • TABLE 9 LAMEA Others Market by Country, 2018 - 2021, USD Million
  • TABLE 10 LAMEA Others Market by Country, 2022 - 2028, USD Million
  • TABLE 11 LAMEA Intravenous Immunoglobulin Market by Application, 2018 - 2021, USD Million
  • TABLE 12 LAMEA Intravenous Immunoglobulin Market by Application, 2022 - 2028, USD Million
  • TABLE 13 LAMEA Immunodeficiency Diseases Market by Country, 2018 - 2021, USD Million
  • TABLE 14 LAMEA Immunodeficiency Diseases Market by Country, 2022 - 2028, USD Million
  • TABLE 15 LAMEA Chronic Inflammatory Demyelinating Polyneuropathy Market by Country, 2018 - 2021, USD Million
  • TABLE 16 LAMEA Chronic Inflammatory Demyelinating Polyneuropathy Market by Country, 2022 - 2028, USD Million
  • TABLE 17 LAMEA Hypogammaglobulinemia Market by Country, 2018 - 2021, USD Million
  • TABLE 18 LAMEA Hypogammaglobulinemia Market by Country, 2022 - 2028, USD Million
  • TABLE 19 LAMEA Chronic Lymphocytic Leukemia & Myasthenia Gravis Market by Country, 2018 - 2021, USD Million
  • TABLE 20 LAMEA Chronic Lymphocytic Leukemia & Myasthenia Gravis Market by Country, 2022 - 2028, USD Million
  • TABLE 21 LAMEA Congenital AIDS & Multifocal Motor Neuropathy Market by Country, 2018 - 2021, USD Million
  • TABLE 22 LAMEA Congenital AIDS & Multifocal Motor Neuropathy Market by Country, 2022 - 2028, USD Million
  • TABLE 23 LAMEA Kawasaki Disease Market by Country, 2018 - 2021, USD Million
  • TABLE 24 LAMEA Kawasaki Disease Market by Country, 2022 - 2028, USD Million
  • TABLE 25 LAMEA Guillain-Barre Syndrome Market by Country, 2018 - 2021, USD Million
  • TABLE 26 LAMEA Guillain-Barre Syndrome Market by Country, 2022 - 2028, USD Million
  • TABLE 27 LAMEA Immune thrombocytopenia (ITP) Market by Country, 2018 - 2021, USD Million
  • TABLE 28 LAMEA Immune thrombocytopenia (ITP) Market by Country, 2022 - 2028, USD Million
  • TABLE 29 LAMEA Others Market by Country, 2018 - 2021, USD Million
  • TABLE 30 LAMEA Others Market by Country, 2022 - 2028, USD Million
  • TABLE 31 LAMEA Intravenous Immunoglobulin Market by Country, 2018 - 2021, USD Million
  • TABLE 32 LAMEA Intravenous Immunoglobulin Market by Country, 2022 - 2028, USD Million
  • TABLE 33 Brazil Intravenous Immunoglobulin Market, 2018 - 2021, USD Million
  • TABLE 34 Brazil Intravenous Immunoglobulin Market, 2022 - 2028, USD Million
  • TABLE 35 Brazil Intravenous Immunoglobulin Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 36 Brazil Intravenous Immunoglobulin Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 37 Brazil Intravenous Immunoglobulin Market by Application, 2018 - 2021, USD Million
  • TABLE 38 Brazil Intravenous Immunoglobulin Market by Application, 2022 - 2028, USD Million
  • TABLE 39 Argentina Intravenous Immunoglobulin Market, 2018 - 2021, USD Million
  • TABLE 40 Argentina Intravenous Immunoglobulin Market, 2022 - 2028, USD Million
  • TABLE 41 Argentina Intravenous Immunoglobulin Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 42 Argentina Intravenous Immunoglobulin Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 43 Argentina Intravenous Immunoglobulin Market by Application, 2018 - 2021, USD Million
  • TABLE 44 Argentina Intravenous Immunoglobulin Market by Application, 2022 - 2028, USD Million
  • TABLE 45 UAE Intravenous Immunoglobulin Market, 2018 - 2021, USD Million
  • TABLE 46 UAE Intravenous Immunoglobulin Market, 2022 - 2028, USD Million
  • TABLE 47 UAE Intravenous Immunoglobulin Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 48 UAE Intravenous Immunoglobulin Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 49 UAE Intravenous Immunoglobulin Market by Application, 2018 - 2021, USD Million
  • TABLE 50 UAE Intravenous Immunoglobulin Market by Application, 2022 - 2028, USD Million
  • TABLE 51 Saudi Arabia Intravenous Immunoglobulin Market, 2018 - 2021, USD Million
  • TABLE 52 Saudi Arabia Intravenous Immunoglobulin Market, 2022 - 2028, USD Million
  • TABLE 53 Saudi Arabia Intravenous Immunoglobulin Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 54 Saudi Arabia Intravenous Immunoglobulin Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 55 Saudi Arabia Intravenous Immunoglobulin Market by Application, 2018 - 2021, USD Million
  • TABLE 56 Saudi Arabia Intravenous Immunoglobulin Market by Application, 2022 - 2028, USD Million
  • TABLE 57 South Africa Intravenous Immunoglobulin Market, 2018 - 2021, USD Million
  • TABLE 58 South Africa Intravenous Immunoglobulin Market, 2022 - 2028, USD Million
  • TABLE 59 South Africa Intravenous Immunoglobulin Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 60 South Africa Intravenous Immunoglobulin Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 61 South Africa Intravenous Immunoglobulin Market by Application, 2018 - 2021, USD Million
  • TABLE 62 South Africa Intravenous Immunoglobulin Market by Application, 2022 - 2028, USD Million
  • TABLE 63 Nigeria Intravenous Immunoglobulin Market, 2018 - 2021, USD Million
  • TABLE 64 Nigeria Intravenous Immunoglobulin Market, 2022 - 2028, USD Million
  • TABLE 65 Nigeria Intravenous Immunoglobulin Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 66 Nigeria Intravenous Immunoglobulin Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 67 Nigeria Intravenous Immunoglobulin Market by Application, 2018 - 2021, USD Million
  • TABLE 68 Nigeria Intravenous Immunoglobulin Market by Application, 2022 - 2028, USD Million
  • TABLE 69 Rest of LAMEA Intravenous Immunoglobulin Market, 2018 - 2021, USD Million
  • TABLE 70 Rest of LAMEA Intravenous Immunoglobulin Market, 2022 - 2028, USD Million
  • TABLE 71 Rest of LAMEA Intravenous Immunoglobulin Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 72 Rest of LAMEA Intravenous Immunoglobulin Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 73 Rest of LAMEA Intravenous Immunoglobulin Market by Application, 2018 - 2021, USD Million
  • TABLE 74 Rest of LAMEA Intravenous Immunoglobulin Market by Application, 2022 - 2028, USD Million
  • TABLE 75 Key information - Grifols, S.A.
  • TABLE 76 Key Information - Takeda Pharmaceutical Company Limited
  • TABLE 77 Key Information - Baxter International, Inc.
  • TABLE 78 key information - Biotest AG
  • TABLE 79 Key Information - LFB S.A
  • TABLE 80 key Information - CSL Limited
  • TABLE 81 Key Information - Octapharma AG
  • TABLE 82 key Information - Kedrion S.p.A
  • TABLE 83 Key Information - Bayer AG

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Recent strategies and developments: Grifols, S.A.
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!